Abbott Laboratories Stock Price, News & Analysis (NYSE:ABT)

$58.99 0.55 (0.94 %)
(As of 01/18/2018 02:31 PM ET)
Previous Close$58.44
Today's Range$58.62 - $59.10
52-Week Range$39.25 - $59.60
Volume5.04 million shs
Average Volume6.17 million shs
Market Capitalization$102.28 billion
P/E Ratio48.75
Dividend Yield1.90%
Beta1.55

About Abbott Laboratories (NYSE:ABT)

Abbott Laboratories logoAbbott Laboratories is engaged in the discovery, development, manufacture and sale of a range of healthcare products. The Company operates through four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products and Vascular Products. Its Established Pharmaceutical Products include a range of branded generic pharmaceuticals manufactured around the world and marketed and sold outside the United States. Its Diagnostic Products include a range of diagnostic systems and tests. Its Nutritional Products include a range of pediatric and adult nutritional products. Its Company's Vascular Products include a range of coronary, endovascular, vessel closure and structural heart devices for the treatment of vascular disease. The Company, through St. Jude Medical, Inc., also offers products, such as rhythm management products, electrophysiology products, heart failure related products, vascular products, structural heart products and neuromodulation products.

Receive ABT News and Ratings via Email

Sign-up to receive the latest news and ratings for ABT and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceuticals
Sub-IndustryHealth Care Equipment
SectorHealthcare
SymbolNYSE:ABT
CUSIP00282410
Phone+1-847-9376100

Debt

Debt-to-Equity Ratio0.72%
Current Ratio2.69%
Quick Ratio2.26%

Price-To-Earnings

Trailing P/E Ratio48.7520661157025
Forward P/E Ratio23.60
P/E Growth1.86

Sales & Book Value

Annual Sales$20.85 billion
Price / Sales4.92
Cash Flow$2.81 per share
Price / Cash20.96
Book Value$12.04 per share
Price / Book4.90

Profitability

Trailing EPS$1.21
Net Income$1.40 billion
Net Margins8.37%
Return on Equity13.98%
Return on Assets6.09%

Miscellaneous

Employees75,000
Outstanding Shares1,740,600,000

Abbott Laboratories (NYSE:ABT) Frequently Asked Questions

What is Abbott Laboratories' stock symbol?

Abbott Laboratories trades on the New York Stock Exchange (NYSE) under the ticker symbol "ABT."

How often does Abbott Laboratories pay dividends? What is the dividend yield for Abbott Laboratories?

Abbott Laboratories declared a quarterly dividend on Friday, December 15th. Shareholders of record on Friday, January 12th will be paid a dividend of $0.28 per share on Thursday, February 15th. This represents a $1.12 annualized dividend and a yield of 1.90%. The ex-dividend date of this dividend is Thursday, January 11th. This is a boost from Abbott Laboratories's previous quarterly dividend of $0.27. View Abbott Laboratories' Dividend History.

How were Abbott Laboratories' earnings last quarter?

Abbott Laboratories (NYSE:ABT) released its quarterly earnings data on Wednesday, October, 18th. The healthcare product maker reported $0.66 earnings per share for the quarter, beating the Zacks' consensus estimate of $0.65 by $0.01. The healthcare product maker had revenue of $6.83 billion for the quarter, compared to the consensus estimate of $6.72 billion. Abbott Laboratories had a net margin of 8.37% and a return on equity of 13.98%. The company's quarterly revenue was up 28.8% on a year-over-year basis. During the same quarter last year, the business posted $0.59 EPS. View Abbott Laboratories' Earnings History.

When will Abbott Laboratories make its next earnings announcement?

Abbott Laboratories is scheduled to release their next quarterly earnings announcement on Wednesday, January, 24th 2018. View Earnings Estimates for Abbott Laboratories.

Where is Abbott Laboratories' stock going? Where will Abbott Laboratories' stock price be in 2018?

15 brokers have issued 1-year target prices for Abbott Laboratories' stock. Their forecasts range from $45.00 to $68.00. On average, they expect Abbott Laboratories' share price to reach $61.27 in the next year. View Analyst Ratings for Abbott Laboratories.

Who are some of Abbott Laboratories' key competitors?

Who are Abbott Laboratories' key executives?

Abbott Laboratories' management team includes the folowing people:

  • Miles D. White, Chairman of the Board, Chief Executive Officer (Age 62)
  • Brian B. Yoor, Chief Financial Officer, Senior Vice President - Finance (Age 47)
  • Michael T. Rousseau, President - Cardiovascular and Neuromodulation (Age 61)
  • Hubert L. Allen, Executive Vice President, General Counsel, Secretary (Age 51)
  • Stephen R. Fussell, Executive Vice President - Human Resources (Age 59)
  • Brian J. Blaser, Executive Vice President - Diagnostics Products (Age 52)
  • John M. Capek Ph.D., Executive Vice President - Ventures (Age 55)
  • Robert B. Ford, Executive Vice President - Medical Devices (Age 43)
  • Heather L. Mason, Executive Vice President - Nutritional Products (Age 56)
  • Roger M Bird, Senior Vice President - U.S. Nutrition (Age 60)

Who owns Abbott Laboratories stock?

Abbott Laboratories' stock is owned by many different of institutional and retail investors. Top institutional shareholders include Schwab Charles Investment Management Inc. (0.40%), Vontobel Asset Management Inc. (0.18%), Bank of Montreal Can (0.17%), National Pension Service (0.08%), Hexavest Inc. (0.06%) and Gateway Investment Advisers LLC (0.05%). Company insiders that own Abbott Laboratories stock include Alejandro D Wellisch, Brian B Yoor, Brian J Blaser, Daniel Gesua Sive Salvadori, Deepak S Nath, Heather L Mason, Hubert L Allen, Jaime Contreras, Jared Watkin, Joseph J Manning, Michael J Warmuth, Miles D White, Robert B Ford, Robert E Funck, Roger Bird, Sally E Blount, Sharon J Bracken and Stephen R Fussell. View Institutional Ownership Trends for Abbott Laboratories.

Who sold Abbott Laboratories stock? Who is selling Abbott Laboratories stock?

Abbott Laboratories' stock was sold by a variety of institutional investors in the last quarter, including Cullinan Associates Inc., Gateway Investment Advisers LLC, Sit Investment Associates Inc., Benin Management CORP, Exxonmobil Investment Management Inc. TX, Dalton Greiner Hartman Maher & Co., Stralem & Co. Inc. and Livforsakringsbolaget Skandia Omsesidigt. Company insiders that have sold Abbott Laboratories company stock in the last year include Alejandro D Wellisch, Brian J Blaser, Daniel Gesua Sive Salvadori, Deepak S Nath, Heather L Mason, Hubert L Allen, Jaime Contreras, Jared Watkin, Joseph J Manning, Michael J Warmuth, Miles D White, Robert E Funck, Roger Bird, Sharon J Bracken and Stephen R Fussell. View Insider Buying and Selling for Abbott Laboratories.

Who bought Abbott Laboratories stock? Who is buying Abbott Laboratories stock?

Abbott Laboratories' stock was bought by a variety of institutional investors in the last quarter, including Bank of Montreal Can, Schwab Charles Investment Management Inc., Carlson Capital Management, National Pension Service, Creative Planning, Sawyer & Company Inc, Hexavest Inc. and Koshinski Asset Management Inc.. Company insiders that have bought Abbott Laboratories stock in the last two years include Brian J Blaser, Miles D White, Robert B Ford and Sally E Blount. View Insider Buying and Selling for Abbott Laboratories.

How do I buy Abbott Laboratories stock?

Shares of Abbott Laboratories can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Abbott Laboratories' stock price today?

One share of Abbott Laboratories stock can currently be purchased for approximately $58.99.

How big of a company is Abbott Laboratories?

Abbott Laboratories has a market capitalization of $102.28 billion and generates $20.85 billion in revenue each year. The healthcare product maker earns $1.40 billion in net income (profit) each year or $1.21 on an earnings per share basis. Abbott Laboratories employs 75,000 workers across the globe.

How can I contact Abbott Laboratories?

Abbott Laboratories' mailing address is 100 Abbott Park Rd, ABBOTT PARK, IL 60064-3500, United States. The healthcare product maker can be reached via phone at +1-847-9376100.


MarketBeat Community Rating for Abbott Laboratories (ABT)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  612 (Vote Outperform)
Underperform Votes:  462 (Vote Underperform)
Total Votes:  1,074
MarketBeat's community ratings are surveys of what our community members think about Abbott Laboratories and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Abbott Laboratories (NYSE:ABT) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.872.712.642.79
Ratings Breakdown: 0 Sell Rating(s)
2 Hold Rating(s)
13 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
4 Hold Rating(s)
10 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
5 Hold Rating(s)
9 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
3 Hold Rating(s)
11 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $61.27$58.50$57.64$52.77
Price Target Upside: 3.98% upside6.48% upside3.36% upside3.79% upside

Abbott Laboratories (NYSE:ABT) Consensus Price Target History

Price Target History for Abbott Laboratories (NYSE:ABT)

Abbott Laboratories (NYSE:ABT) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
1/9/2018Royal Bank of CanadaReiterated RatingBuy$65.00LowView Rating Details
1/8/2018BarclaysReiterated RatingBuy$66.00LowView Rating Details
1/3/2018Evercore ISIInitiated CoverageOutperform -> Outperform$64.00LowView Rating Details
1/2/2018JPMorgan Chase & Co.UpgradeNeutral -> Overweight$60.00 -> $60.00LowView Rating Details
1/2/2018Morgan StanleyUpgradeEqual Weight -> Overweight$67.00LowView Rating Details
12/12/2017BMO Capital MarketsUpgradeMarket Perform -> Outperform$58.00 -> $65.00MediumView Rating Details
10/19/2017CitigroupReiterated RatingNeutralN/AView Rating Details
10/19/2017CowenSet Price TargetBuy$55.00 -> $68.00N/AView Rating Details
10/19/2017Stifel NicolausBoost Price TargetBuy -> Buy$58.00 -> $63.00N/AView Rating Details
10/19/2017Jefferies GroupReiterated RatingBuy$65.00N/AView Rating Details
10/4/2017Bank of AmericaReiterated RatingBuy$56.00 -> $60.00N/AView Rating Details
9/28/2017Wells Fargo & CoBoost Price TargetOutperform$57.00 -> $64.00LowView Rating Details
6/29/2017GuggenheimInitiated CoverageBuy$58.00LowView Rating Details
6/21/2017BTIG ResearchInitiated CoverageBuy$56.00LowView Rating Details
5/16/2017Goldman Sachs GroupInitiated CoverageNeutral -> Neutral$45.00LowView Rating Details
8/9/2016Deutsche BankReiterated RatingBuyN/AView Rating Details
7/28/2016ArgusReiterated RatingBuy$55.00N/AView Rating Details
6/21/2016Edward JonesUpgradeHold -> BuyN/AView Rating Details
6/8/2016Credit Suisse GroupReiterated RatingBuyN/AView Rating Details
4/30/2016S&P Equity ResearchReiterated RatingHoldN/AView Rating Details
4/30/2016GabelliReiterated RatingBuyN/AView Rating Details
4/28/2016Piper Jaffray CompaniesDowngradeOverweight -> NeutralN/AView Rating Details
4/14/2016First GlobalDowngradeOutperform -> MarketperformN/AView Rating Details
3/28/2016Leerink SwannBoost Price TargetMarket Perform$37.00 -> $40.00N/AView Rating Details
1/29/2016Raymond James FinancialLower Price TargetOutperform$46.00 -> $42.00N/AView Rating Details
1/29/2016William BlairDowngradeOutperform -> Market PerformN/AView Rating Details
(Data available from 1/18/2016 forward)

Earnings

Abbott Laboratories (NYSE:ABT) Earnings History and Estimates Chart

Earnings by Quarter for Abbott Laboratories (NYSE:ABT)

Abbott Laboratories (NYSE ABT) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
1/24/2018$0.73N/AView Earnings Details
10/18/20179/30/2017$0.65$0.66$6.72 billion$6.83 billionViewN/AView Earnings Details
7/20/2017Q2 2017$0.60$0.62$6.63 billion$6.64 billionViewN/AView Earnings Details
4/19/20173/31/2017$0.43$0.48$6.16 billion$6.34 billionViewN/AView Earnings Details
1/25/2017Q416$0.64$0.65$5.41 billion$5.33 billionViewListenView Earnings Details
10/19/2016Q316$0.58$0.59$5.29 billion$5.30 billionViewListenView Earnings Details
7/20/2016Q216$0.53$0.55$5.24 billion$5.30 billionViewListenView Earnings Details
4/20/2016Q116$0.39$0.41$4.77 billion$4.90 billionViewListenView Earnings Details
1/28/2016Q415$0.61$0.62$5.31 billion$5.20 billionViewListenView Earnings Details
10/21/2015Q315$0.53$0.54$5.16 billion$5.15 billionViewListenView Earnings Details
7/22/2015Q215$0.50$0.52$5.15 billion$5.20 billionViewListenView Earnings Details
4/22/2015Q115$0.42$0.47$4.85 billion$4.90 billionViewListenView Earnings Details
1/29/2015Q414$0.68$0.71$5.48 billion$5.36 billionViewListenView Earnings Details
10/22/2014Q314$0.60$0.62$5.62 billion$5.10 billionViewListenView Earnings Details
7/16/2014Q214$0.51$0.54$5.53 billion$5.55 billionViewListenView Earnings Details
4/16/2014Q114$0.36$0.41$5.29 billion$5.24 billionViewListenView Earnings Details
1/22/2014Q413$0.58$0.58$5.72 billion$5.66 billionViewListenView Earnings Details
10/16/2013Q313$0.52$0.55$5.46 billion$5.37 billionViewListenView Earnings Details
7/17/2013Q2 2013$0.44$0.46$5.53 billion$5.45 billionViewListenView Earnings Details
4/17/2013Q1 2013$0.41$0.42$5.42 billion$5.38 billionViewListenView Earnings Details
1/23/2013Q4 2012$1.50$1.51$10.58 billion$10.80 billionViewListenView Earnings Details
10/17/2012$1.28$1.30ViewN/AView Earnings Details
7/18/2012$1.22$1.23ViewN/AView Earnings Details
4/18/2012$1.00$1.03ViewN/AView Earnings Details
1/25/2012$1.44$1.45ViewN/AView Earnings Details
10/19/2011$1.17$1.18ViewN/AView Earnings Details
7/20/2011$1.12$1.12ViewN/AView Earnings Details
4/20/2011$0.90$0.91ViewN/AView Earnings Details
1/26/2011$1.29$1.30ViewN/AView Earnings Details
10/20/2010Q3 2010$1.04$1.05ViewN/AView Earnings Details
7/21/2010Q2 2010$1.00$1.01ViewN/AView Earnings Details
4/21/2010Q1 2010$0.80$0.81ViewN/AView Earnings Details
1/27/2010Q4 2009$1.17$1.18ViewN/AView Earnings Details
10/14/2009Q3 2009$0.90$0.92ViewN/AView Earnings Details
7/15/2009Q2 2009$0.89$0.90ViewN/AView Earnings Details
4/15/2009Q1 2009$0.70$0.73ViewN/AView Earnings Details
1/21/2009Q4 2008$1.06$1.06ViewN/AView Earnings Details
10/15/2008Q3 2008$0.77$0.79ViewN/AView Earnings Details
7/16/2008Q2 2008$0.78$0.84ViewN/AView Earnings Details
4/16/2008Q1 2008$0.63$0.63ViewN/AView Earnings Details
1/23/2008Q4 2007$0.92$0.93ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Abbott Laboratories (NYSE:ABT) Earnings Estimates

2018 EPS Consensus Estimate: $2.84
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20183$0.56$0.58$0.57
Q2 20183$0.71$0.72$0.72
Q3 20183$0.76$0.77$0.76
Q4 20183$0.78$0.80$0.79
(Earnings estimates data provided by Zacks Investment Research)

Dividends

Abbott Laboratories (NYSE:ABT) Dividend Information

Next Dividend:2/15/2018
Annual Dividend:$1.12
Dividend Yield:1.90%
Dividend Growth:6.40% (3 Year Average)
Payout Ratio:92.56% (Trailing 12 Months of Earnings)
44.80% (Based on This Year's Estimates)
39.58% (Based on Next Year's Estimates)
Track Record:45 Years of Consecutive Dividend Growth
Frequency:Quarterly Dividend
Dividend Payments by Quarter for Abbott Laboratories (NYSE:ABT)

Abbott Laboratories (NYSE:ABT) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
12/15/2017quarterly$0.281.99%1/11/20181/12/20182/15/2018
9/15/2017quarterly$0.272.05%10/12/201710/13/201711/15/2017
6/9/2017quarterly$0.272.25%7/12/20177/14/20178/15/2017
2/17/2017quarterly$0.272.36%4/11/20174/14/20175/15/2017
12/9/2016quarterly$0.272.7%1/11/20171/13/20172/15/2017
9/15/2016quarterly$0.262.48%10/12/201610/14/201611/15/2016
6/10/2016quarterly$0.262.75%7/13/20167/15/20168/15/2016
2/19/2016quarterly$0.262.66%4/13/20164/15/20165/16/2016
12/11/2015quarterly$0.262.32%1/13/20161/15/20162/16/2016
9/17/2015quarterly$0.242.22%10/13/201510/15/201511/15/2015
6/12/2015quarterly$0.242%7/13/20157/15/20158/15/2015
2/20/2015quarterly$0.242.03%4/13/20154/15/20155/15/2015
12/12/2014quarterly$0.242.21%1/13/20151/15/20152/13/2015
9/11/2014quarterly$0.222.07%10/10/201410/15/201411/15/2014
6/13/2014quarterly$0.222.21%7/11/20147/15/20148/15/2014
2/21/2014quarterly$0.222.26%4/11/20144/15/20145/15/2014
10/16/2013quarterly$0.222.37%1/13/20141/15/20142/15/2014
9/12/2013quarterly$0.141.61%10/10/201310/15/201311/15/2013
6/14/2013quarterly$0.141.52%7/11/20137/15/20138/15/2013
2/15/2013quarterly$0.141.61%4/11/20134/15/20135/15/2013
12/14/2012quarterly$0.140.86%1/11/20131/15/20132/15/2013
(Data available from 1/1/2013 forward)

Insider Trades

Abbott Laboratories (NYSE ABT) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 0.76%
Institutional Ownership Percentage: 71.19%
Insider Trades by Quarter for Abbott Laboratories (NYSE:ABT)
Institutional Ownership by Quarter for Abbott Laboratories (NYSE:ABT)

Abbott Laboratories (NYSE ABT) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
12/14/2017Daniel Gesua Sive SalvadoriInsiderSell28,319$54.92$1,555,279.48102,117View SEC Filing  
12/6/2017Miles D WhiteChairmanSell276,886$54.41$15,065,367.263,677,913View SEC Filing  
11/30/2017Sharon J BrackenInsiderSell2,188$56.12$122,790.5625,618View SEC Filing  
11/22/2017Alejandro D WellischInsiderSell2,153$55.86$120,266.5810,256View SEC Filing  
11/17/2017Brian J BlaserInsiderSell23,866$55.55$1,325,756.30146,387View SEC Filing  
11/14/2017Daniel Gesua Sive SalvadoriInsiderSell71,157$55.00$3,913,635.00144,955View SEC Filing  
10/23/2017Daniel Gesua Sive SalvadoriEVPSell96,603$56.21$5,430,054.63142,082View SEC Filing  
9/26/2017Daniel Gesua Sive SalvadoriInsiderSell62,460$52.95$3,307,257.00113,426View SEC Filing  
9/22/2017Jaime ContrerasInsiderSell52,700$51.97$2,738,819.0058,739View SEC Filing  
8/16/2017Stephen R FussellInsiderSell196,550$49.50$9,729,225.00221,488View SEC Filing  
8/1/2017Sharon J BrackenInsiderSell2,000$49.16$98,320.0028,806View SEC Filing  
7/27/2017Brian J BlaserInsiderSell15,000$50.00$750,000.00143,154View SEC Filing  
7/25/2017Hubert L AllenInsiderSell4,600$50.79$233,634.00105,479View SEC Filing  
6/15/2017Jared WatkinInsiderSell552$47.97$26,479.4447,090View SEC Filing  
6/8/2017Stephen R FussellInsiderSell196,550$46.00$9,041,300.00221,488View SEC Filing  
4/27/2017Roger BirdInsiderSell5,600$43.82$245,392.0051,313View SEC Filing  
4/26/2017Joseph J ManningInsiderSell4,200$43.95$184,590.0026,224View SEC Filing  
3/1/2017Michael J. WarmuthInsiderSell3,851$45.39$174,796.89View SEC Filing  
2/23/2017Robert E FunckVPSell25,500$45.50$1,160,250.00117,579View SEC Filing  
2/22/2017Roger BirdInsiderSell13,222$45.02$595,254.4463,910View SEC Filing  
2/21/2017Deepak S NathInsiderSell319$44.98$14,348.6258,471View SEC Filing  
1/31/2017Heather L MasonInsiderSell35,700$40.77$1,455,489.00100,189View SEC Filing  
12/20/2016Brian J BlaserInsiderBuy15,580$38.45$599,051.00129,782View SEC Filing  
12/14/2016Robert B FordInsiderBuy12,775$39.09$499,374.7551,532View SEC Filing  
11/10/2016Miles D WhiteChairmanBuy121,456$40.45$4,912,895.202,802,558View SEC Filing  
11/1/2016Sally E BlountDirectorBuy5,100$39.24$200,124.0020,143View SEC Filing  
9/26/2016Daniel Gesua Sive SalvadoriSVPSell815$41.71$33,993.6559,791View SEC Filing  
7/28/2016Stephen R FussellInsiderSell41,500$45.00$1,867,500.00196,467View SEC Filing  
7/26/2016Michael J WarmuthInsiderSell26,800$43.49$1,165,532.0081,811View SEC Filing  
7/25/2016Miles D WhiteChairmanBuy242,547$43.18$10,473,179.462,010,517View SEC Filing  
7/25/2016Robert E FunckVPSell26,800$43.08$1,154,544.00111,819View SEC Filing  
6/28/2016Hubert L AllenEVPSell3,400$37.14$126,276.0091,857View SEC Filing  
6/15/2016Jared WatkinSVPSell552$37.63$20,771.7647,114View SEC Filing  
6/1/2016Brian B YoorCFOSell565$39.49$22,311.8550,182View SEC Filing  
4/28/2016Deepak S NathSVPSell53$41.31$2,189.4347,435View SEC Filing  
3/31/2016Jaime ContrerasSVPSell462$41.78$19,302.3647,667View SEC Filing  
2/29/2016Brian B YoorCFOSell865$39.12$33,838.8052,250View SEC Filing  
2/29/2016Deepak S NathSVPSell793$39.27$31,141.1148,364View SEC Filing  
2/29/2016Robert B FordEVPSell1,706$39.28$67,011.6862,495View SEC Filing  
2/29/2016Robert E FunckVPSell1,333$39.30$52,386.9086,352View SEC Filing  
2/22/2016Jared WatkinSVPSell554$39.09$21,655.8650,515View SEC Filing  
2/16/2016Deepak S. NathSVPSell171$37.13$6,349.2334,941View SEC Filing  
12/16/2015Miles D. WhiteCEOSell438,000$46.00$20,148,000.001,394,153View SEC Filing  
8/18/2015Stephen R. FussellEVPSell13,096$50.46$660,824.16130,601View SEC Filing  
4/27/2015Heather L MasonEVPSell13,500$47.45$640,575.00View SEC Filing  
4/27/2015Roger BirdSVPSell28,548$47.57$1,358,028.36View SEC Filing  
3/26/2015J. Scott WhiteSVPSell12,483$46.68$582,706.44View SEC Filing  
3/2/2015Jaime ContrerasSVPSell9,209$47.34$435,954.06View SEC Filing  
2/4/2015John M CapekEVPSell34,292$45.66$1,565,772.72View SEC Filing  
11/25/2014Jaime ContrerasSVPSell51,600$44.07$2,274,012.00View SEC Filing  
10/29/2014Miles D WhiteCEOSell440,800$42.52$18,742,816.00View SEC Filing  
3/3/2014John LandgrafEVPSell17,293$39.38$680,998.3495,131View SEC Filing  
3/3/2014Katherine DoyleSVPSell6,639$39.01$258,987.3947,525View SEC Filing  
3/3/2014Robert FunckVPSell1,413$38.97$55,064.6162,926View SEC Filing  
2/18/2014John LandgrafEVPSell1,583$39.10$61,895.30102,421View SEC Filing  
1/29/2014Michael WarmuthEVPSell11,430$36.21$413,880.3040,487View SEC Filing  
12/6/2013Jean-Yves PaveeSVPSell5,855$37.46$219,328.3030,901View SEC Filing  
11/7/2013Stephen FussellEVPSell10,466$37.59$393,416.94101,169View SEC Filing  
10/30/2013Jaime ContrerasSVPSell25,368$36.85$934,810.80View SEC Filing  
6/7/2013Heather L MasonSVPSell12,000$37.01$444,120.00View SEC Filing  
2/1/2013William A OsbornDirectorBuy10,000$33.86$338,600.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Abbott Laboratories (NYSE ABT) News Headlines

Source:
DateHeadline
Can EPD & Medical Devices Drive Abbott's (ABT) Q4 Earnings?Can EPD & Medical Devices Drive Abbott's (ABT) Q4 Earnings?
finance.yahoo.com - January 18 at 7:52 AM
S&P 500 Analyst Moves: ABTS&P 500 Analyst Moves: ABT
www.nasdaq.com - January 17 at 3:22 PM
Abbott Laboratories (ABT) Scheduled to Post Earnings on WednesdayAbbott Laboratories (ABT) Scheduled to Post Earnings on Wednesday
www.americanbankingnews.com - January 17 at 1:28 AM
Abbott Laboratories Target of Unusually High Options Trading (ABT)Abbott Laboratories Target of Unusually High Options Trading (ABT)
www.americanbankingnews.com - January 13 at 4:26 AM
Abbott Laboratories (ABT) Ex-Dividend Date Scheduled for January 11, 2018 - NasdaqAbbott Laboratories (ABT) Ex-Dividend Date Scheduled for January 11, 2018 - Nasdaq
www.nasdaq.com - January 11 at 7:21 AM
Notable Wednesday Option Activity: ABT, NOV, JPMNotable Wednesday Option Activity: ABT, NOV, JPM
www.nasdaq.com - January 10 at 3:23 PM
What’s Driving Baxter International’s Cash Flow GrowthWhat’s Driving Baxter International’s Cash Flow Growth
finance.yahoo.com - January 10 at 7:44 AM
Amgen (AMGN) and Abbott Laboratories (ABT) Head-To-Head ComparisonAmgen (AMGN) and Abbott Laboratories (ABT) Head-To-Head Comparison
www.americanbankingnews.com - January 10 at 1:16 AM
Abbott Laboratories (ABT) Management Presents at 36th Annual JPMorgan Healthcare Conference (Transcript) - Seeking AlphaAbbott Laboratories' (ABT) Management Presents at 36th Annual JPMorgan Healthcare Conference (Transcript) - Seeking Alpha
seekingalpha.com - January 9 at 7:57 AM
Abbott Laboratories (ABT) Earns "Buy" Rating from BarclaysAbbott Laboratories (ABT) Earns "Buy" Rating from Barclays
www.americanbankingnews.com - January 8 at 8:48 AM
 Brokerages Expect Abbott Laboratories (ABT) Will Announce Quarterly Sales of $7.37 Billion Brokerages Expect Abbott Laboratories (ABT) Will Announce Quarterly Sales of $7.37 Billion
www.americanbankingnews.com - January 6 at 2:00 AM
$0.73 Earnings Per Share Expected for Abbott Laboratories (ABT) This Quarter$0.73 Earnings Per Share Expected for Abbott Laboratories (ABT) This Quarter
www.americanbankingnews.com - January 4 at 9:42 PM
Abbotts Revolutionary Continuous Glucose Monitoring System, FreeStyle® Libre, Now Available To Medicare PatientsAbbott's Revolutionary Continuous Glucose Monitoring System, FreeStyle® Libre, Now Available To Medicare Patients
finance.yahoo.com - January 4 at 3:22 PM
Medicare to cover new glucose monitor, giving Abbott an edge over rival DexcomMedicare to cover new glucose monitor, giving Abbott an edge over rival Dexcom
finance.yahoo.com - January 4 at 3:22 PM
Premarket analyst action - new coverage - healthcare - Seeking AlphaPremarket analyst action - new coverage - healthcare - Seeking Alpha
seekingalpha.com - January 4 at 7:27 AM
New FDA MR-Conditional Labeling Approvals Further Expand Abbotts Portfolio of MRI-Ready DevicesNew FDA MR-Conditional Labeling Approvals Further Expand Abbott's Portfolio of MRI-Ready Devices
finance.yahoo.com - January 3 at 11:09 AM
Abbott Launches Alinity™ h-series Integrated Hematology System, Combining Speed, Accuracy and Seamless IntegrationAbbott Launches Alinity™ h-series Integrated Hematology System, Combining Speed, Accuracy and Seamless Integration
finance.yahoo.com - January 2 at 8:26 PM
Abbott Labs Has An Emerging Picture Of Top-Tier Growth, Says Morgan StanleyAbbott Labs Has 'An Emerging Picture Of Top-Tier Growth,' Says Morgan Stanley
finance.yahoo.com - January 2 at 8:26 PM
Top Analyst Upgrades and Downgrades: Abbott Labs, Delphi, Lululemon, Netflix, Nordstrom, Sirius XM, Disney ... - 24/7 Wall St.Top Analyst Upgrades and Downgrades: Abbott Labs, Delphi, Lululemon, Netflix, Nordstrom, Sirius XM, Disney ... - 24/7 Wall St.
247wallst.com - January 2 at 3:25 PM
Morgan Stanley Upgrades Abbott Labs (ABT) to Overweight, Premium Growth Deserves A Premium Multiple - StreetInsider.comMorgan Stanley Upgrades Abbott Labs (ABT) to Overweight, Premium Growth Deserves A Premium Multiple - StreetInsider.com
www.streetinsider.com - January 2 at 7:38 AM
Abbott Labs (ABT) PT Raised to $68 at Guggenheim; Added to Best Ideas List - StreetInsider.comAbbott Labs (ABT) PT Raised to $68 at Guggenheim; Added to Best Ideas List - StreetInsider.com
www.streetinsider.com - January 2 at 7:38 AM
Abbott Laboratories (ABT) Downgraded to "Hold" at ValuEngineAbbott Laboratories (ABT) Downgraded to "Hold" at ValuEngine
www.americanbankingnews.com - December 30 at 11:18 AM
ETFs with exposure to Abbott Laboratories : December 28, 2017ETFs with exposure to Abbott Laboratories : December 28, 2017
finance.yahoo.com - December 28 at 4:30 PM
What Should Investors Know About Abbott Laboratories’s (NYSE:ABT) Earnings Outlook?What Should Investors Know About Abbott Laboratories’s (NYSE:ABT) Earnings Outlook?
finance.yahoo.com - December 27 at 3:09 PM
Spinal-Cord Implants to Numb Pain Emerge as Alternative to PillsSpinal-Cord Implants to Numb Pain Emerge as Alternative to Pills
finance.yahoo.com - December 26 at 1:12 PM
Abbott Laboratories (ABT) Given Average Rating of "Buy" by BrokeragesAbbott Laboratories (ABT) Given Average Rating of "Buy" by Brokerages
www.americanbankingnews.com - December 26 at 7:54 AM
Apple Reverses Higher; Will Bitcoin ETF End Its Losing Streak?Apple Reverses Higher; Will Bitcoin ETF End Its Losing Streak?
finance.yahoo.com - December 22 at 3:38 PM
Top Research Reports for Pfizer, FedEx & AbbottTop Research Reports for Pfizer, FedEx & Abbott
finance.yahoo.com - December 22 at 7:21 AM
Abbott (ABT) at a 52-Week High: What's Driving the Stock?Abbott (ABT) at a 52-Week High: What's Driving the Stock?
finance.yahoo.com - December 21 at 3:22 PM
Abbott Laboratories (ABT) Expected to Announce Quarterly Sales of $7.37 BillionAbbott Laboratories (ABT) Expected to Announce Quarterly Sales of $7.37 Billion
www.americanbankingnews.com - December 21 at 9:12 AM
Year-End Portfolio Pruning, Part 2: Abbott Labs: Buy The Rumor, Sell The News - Seeking AlphaYear-End Portfolio Pruning, Part 2: Abbott Labs: Buy The Rumor, Sell The News - Seeking Alpha
seekingalpha.com - December 20 at 7:12 AM
Abbott Laboratories (ABT) QuoteAbbott Laboratories (ABT) Quote
www.reuters.com - December 19 at 3:21 PM
Abbott Laboratories – Value Analysis (NYSE:ABT) : December 19, 2017Abbott Laboratories – Value Analysis (NYSE:ABT) : December 19, 2017
finance.yahoo.com - December 19 at 3:21 PM
Abbott Laboratories (ABT) Lowered to Sell at Zacks Investment ResearchAbbott Laboratories (ABT) Lowered to Sell at Zacks Investment Research
www.americanbankingnews.com - December 19 at 9:50 AM
Abbott Laboratories (ABT) Expected to Post Earnings of $0.73 Per ShareAbbott Laboratories (ABT) Expected to Post Earnings of $0.73 Per Share
www.americanbankingnews.com - December 19 at 8:18 AM
Abbott Hosts Conference Call for Fourth-Quarter EarningsAbbott Hosts Conference Call for Fourth-Quarter Earnings
finance.yahoo.com - December 18 at 3:21 PM
Abbott Laboratories breached its 50 day moving average in a Bullish Manner : ABT-US : December 18, 2017Abbott Laboratories breached its 50 day moving average in a Bullish Manner : ABT-US : December 18, 2017
finance.yahoo.com - December 18 at 3:21 PM
BMO Capital Markets Upgrades Abbott Laboratories (ABT) to OutperformBMO Capital Markets Upgrades Abbott Laboratories (ABT) to Outperform
www.americanbankingnews.com - December 17 at 10:44 PM
Abbott Raising Quarterly Dividend for 46th Straight YearAbbott Raising Quarterly Dividend for 46th Straight Year
finance.yahoo.com - December 15 at 3:23 PM
Abbott Laboratories (ABT) to Issue Dividend Increase - $0.28 Per ShareAbbott Laboratories (ABT) to Issue Dividend Increase - $0.28 Per Share
www.americanbankingnews.com - December 15 at 11:28 AM
Abbott Laboratories (ABT) Insider Sells $1,555,279.48 in StockAbbott Laboratories (ABT) Insider Sells $1,555,279.48 in Stock
www.americanbankingnews.com - December 14 at 8:52 PM
Abbott Labs CEO Sells $29 Million in StockAbbott Labs CEO Sells $29 Million in Stock
www.msn.com - December 14 at 3:22 PM
Abbott Laboratories Clears Key Benchmark, Hitting 80-Plus RS RatingAbbott Laboratories Clears Key Benchmark, Hitting 80-Plus RS Rating
finance.yahoo.com - December 14 at 3:22 PM
Abbott Laboratories (ABT) a Buy on Strong Earnings Momentum - Investorplace.comAbbott Laboratories (ABT) a Buy on Strong Earnings Momentum - Investorplace.com
investorplace.com - December 13 at 7:11 AM
[$$] Abbott CEO Sells Stock Near All-Time High[$$] Abbott CEO Sells Stock Near All-Time High
finance.yahoo.com - December 13 at 7:11 AM
Abbott Laboratories Makes BMO Capitals Top Picks List - BenzingaAbbott Laboratories Makes BMO Capital's Top Picks List - Benzinga
www.benzinga.com - December 12 at 3:21 PM
Upgrades & downgrades in the trader blitzUpgrades & downgrades in the trader blitz
finance.yahoo.com - December 12 at 3:21 PM
Raising the Pace: Medical-Device Firms Abbott, Medtronic May Rally in 2018Raising the Pace: Medical-Device Firms Abbott, Medtronic May Rally in 2018
finance.yahoo.com - December 12 at 3:21 PM
Abbott Laboratories (ABT) a Buy on Strong Earnings MomentumAbbott Laboratories (ABT) a Buy on Strong Earnings Momentum
investorplace.com - December 12 at 10:33 AM
ETFs with exposure to Abbott Laboratories : December 11, 2017ETFs with exposure to Abbott Laboratories : December 11, 2017
finance.yahoo.com - December 11 at 3:21 PM

SEC Filings

Abbott Laboratories (NYSE:ABT) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Abbott Laboratories (NYSE:ABT) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Abbott Laboratories (NYSE ABT) Stock Chart for Thursday, January, 18, 2018

Loading chart…

This page was last updated on 1/18/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.